NasdaqGM:SMMTBiotechs
A Look At Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Collaboration
Why the latest FDA filing and GSK collaboration matter for Summit Therapeutics
Summit Therapeutics (SMMT) has drawn fresh attention after filing a Biologics License Application with the FDA for ivonescimab in EGFR-mutated non small cell lung cancer, alongside a new clinical collaboration with GSK across multiple solid tumors.
See our latest analysis for Summit Therapeutics.
The recent FDA Biologics License Application and GSK trial collaboration arrive after a mixed year for the stock, with a...